Short-Term Debt to Equity: haemonetics.com (HAE)

This chart of Haemonetics Corporation (HAE) market price reflects the price action of an asset with a debt-to-equity ratio of 0.00. Haemonetics Corporation is expanding its influence by acquiring small firms specializing in vascular procedures, which offsets stagnation in blood donation. Revenues are driven by the development of advanced plasma collection systems and hemostatics. Its status as a technological behemoth in blood manipulation provides the pricing power to flexibly manage product costs.

To minimize default risks during long-term investing, it is critical to monitor the ratio of liabilities maturing within one year to total equity, which currently stands at 0.00. An analysis of current debt under one year relative to equity confirms the financial stability of Haemonetics Corporation (HAE), whose global network of plants in the US and Asia ensures a stable cash flow to service short-term loans without the threat of a liquidity gap.